60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis

• Market Cap: $6.12M
• Dividend Yield: N/A
• Average Volume (3M): 199.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: 120.67%
• EPS Growth: -456.33%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.16
• Shares Outstanding: 4,104,469
• 10 Day Avg. Volume: 488,900
• 30 Day Avg. Volume: 199,179
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.83
• Enterprise Value/Revenue: 11.62
• Enterprise Value/Gross Profit: 40.22
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: $1.50 ▲(2.74% Upside)

The overall stock score is primarily impacted by the company's financial struggles, including declining revenues and persistent losses. Technical analysis provides some short-term positive signals, but the long-term outlook remains uncertain. The valuation is unattractive due to negative profitability and lack of dividends.

Positive Factors

Product Development

Successful trial outcomes can enhance the company's product portfolio, potentially leading to new revenue streams and strengthening its market position in infectious disease treatment.

Innovative Therapies

Being the first to evaluate a new therapeutic showcases the company's innovation capabilities, potentially offering a competitive advantage in addressing unmet medical needs.

Equity Improvement

Improved equity indicates better financial health and reduced reliance on debt, enhancing the company's ability to invest in growth opportunities and withstand market fluctuations.

Negative Factors

Declining Revenues

Declining revenues highlight challenges in maintaining market share and product demand, which can impact long-term profitability and growth potential.

Negative Cash Flow

Negative cash flow from operations suggests difficulties in generating sufficient cash to cover expenses, potentially limiting investment in R&D and new product development.

Profitability Concerns

Consistently negative profit margins indicate cost management issues and ongoing unprofitability, which can hinder the company's ability to reinvest in growth and innovation.

60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description

60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of infectious diseases. The company operates primarily in the healthcare sector, specializing in drug development aimed at addressing unmet medical needs. Its core products include novel pharmaceutical formulations and delivery systems designed to improve patient outcomes in the management of various infectious diseases.

How the Company Makes Money

60 Degrees Pharmaceuticals generates revenue through the commercialization of its pharmaceutical products, which may include direct sales to healthcare providers and distribution partnerships with pharmaceutical distributors. The company may also derive income from licensing agreements and collaborations with other biopharmaceutical companies, leveraging its research and development capabilities to create valuable intellectual property. Additionally, government grants and funding from research institutions may contribute to its earnings as the company advances its drug development pipeline.

60 Degrees Pharmaceuticals, Inc. Financial Statement Overview

Summary

SXTP is facing significant financial challenges, with declining revenues, persistent losses, and negative cash flow. Despite improvements in equity and reduced debt, profitability and cash generation are major concerns.

Income Statement

The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.

Balance Sheet

The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.

Cash Flow

The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	960.89K	681.35K	253.57K	223.21K	1.16M	2.55M
Gross Profit	277.54K	222.81K	-220.98K	-209.16K	309.60K	1.48M
EBITDA	-7.64M	-7.88M	-1.43M	-2.11M	-1.01M	-341.17K
Net Income	-7.80M	-7.95M	-3.77M	-6.18M	-4.25M	-3.03M
Balance Sheet
Total Assets	4.18M	5.76M	7.78M	1.30M	1.39M	2.61M
Cash, Cash Equivalents and Short-Term Investments	1.97M	3.39M	2.14M	264.87K	115.40K	191.70K
Total Debt	154.25K	155.89K	172.67K	22.42M	18.80M	19.14M
Total Liabilities	1.84M	1.80M	2.99M	25.45M	19.55M	20.68M
Stockholders Equity	2.43M	4.04M	4.87M	-23.58M	-17.58M	-17.50M
Cash Flow
Free Cash Flow	-3.36M	-5.83M	-4.66M	-1.07M	-684.50K	-238.28K
Operating Cash Flow	-3.32M	-5.65M	-4.54M	-1.01M	-649.11K	-167.30K
Investing Cash Flow	-97.91K	-1.89M	-115.89K	-60.13K	-35.39K	-70.98K
Financing Cash Flow	6.85M	7.05M	6.47M	1.22M	611.23K	277.36K

60 Degrees Pharmaceuticals, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 1.51, above the 50-day MA of 1.42, and below the 200-day MA of 2.24, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.11 is Neutral, neither overbought nor oversold. The STOCH value of 12.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.

60 Degrees Pharmaceuticals, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SXTP	46 Neutral	$6.12M	―	-285.78%	―	120.67%	-456.33%
ADIL	32 Underperform	$7.93M	―	-171.27%	―	―	75.96%
DRMA	15 Underperform	$2.71M	―	-231.27%	―	―	85.78%

60 Degrees Pharmaceuticals, Inc. Corporate Events

60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting

On October 8, 2025, 60 Degrees Pharmaceuticals, Inc. held its virtual 2025 Annual Stockholders Meeting, where various proposals were voted on by the shareholders. The meeting saw the election of five directors, approval of an amendment to increase shares in the 2022 Equity Incentive Plan, a reverse stock split, and the ratification of RBSM LLP as the accounting firm for 2025, all of which were approved.

The most recent analyst rating on (SXTP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.

60 Degrees Pharmaceuticals Highlights ARAKODA Growth Potential

On September 9, 2025, 60 Degrees Pharmaceuticals, Inc. presented investor information highlighting the potential growth of ARAKODA, especially for chronic babesiosis, which could surpass its use for malaria prevention. The company faces challenges such as low brand recognition and competition from generic alternatives, but aims to address these through a commercial pilot program to increase awareness and differentiate ARAKODA in the market.

The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.

60 Degrees Pharmaceuticals Enters New Sales Agreement

On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. entered into an At-The-Market Sales Agreement with H.C. Wainwright & Co., LLC to offer and sell shares of its common stock, potentially raising up to $1,397,533. The agreement allows the company flexibility in selling shares while Wainwright acts as the sales agent, earning a 3% commission on sales. Additionally, on the same date, the company terminated a previous sales agreement with Wallachbeth Capital LLC, effective immediately, releasing both parties from any obligations.

The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.

60 Degrees Pharmaceuticals Reports Q2 2025 Earnings

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and marketing new medicines for infectious diseases, with its headquarters in Washington, D.C. The company recently released its earnings report for the second quarter of 2025, highlighting a continued focus on its lead product, ARAKODA®, for malaria prevention, and ongoing development programs for other diseases. Despite a net loss of $1.73 million for the quarter, the company reported a gross profit increase to $50,881, driven by a rise in research revenues. Operating expenses remained high at $1.86 million, primarily due to research and development and general administrative costs. Looking ahead, 60 Degrees Pharmaceuticals plans to continue its efforts to achieve profitability through additional capital raising and strategic initiatives, while addressing the challenges of the competitive biopharmaceutical industry.